C-o- Group In R Patents (Class 514/622)
  • Novel Salicylic Anilides
    Publication number: 20090005434
    Abstract: Novel salicylic anilides are chemical uncouplers useful e.g. for the treatment of obesity.
    Type: Application
    Filed: June 27, 2008
    Publication date: January 1, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Preben Houlberg Olesen, Thomas Kruse Hansen, Lise Brown Christiansen, Holger Claus Hansen
  • Amide Compounds and Their Use
    Publication number: 20080319080
    Abstract: Since an amide compound represented by the formula (1) is effective for controlling plant diseases, it is useful as an effective ingredient of a composition for controlling plant diseases.
    Type: Application
    Filed: October 20, 2006
    Publication date: December 25, 2008
    Inventor: Takashi Komori
  • Laser Marked Dosage Forms
    Publication number: 20080317677
    Abstract: The present invention relates to a coated dosage form having openings to expose the core material or an intermediate coating layer. The invention also relates to methods for manufacturing such coated dosage forms.
    Type: Application
    Filed: June 22, 2007
    Publication date: December 25, 2008
    Inventors: Christopher E. Szymczak, Irvin Matas Lash
  • Methylene-bridged selective androgen receptor modulators and methods of use thereof
    Publication number: 20080319009
    Abstract: This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor.
    Type: Application
    Filed: July 30, 2007
    Publication date: December 25, 2008
    Inventors: James T. Dalton, Duane D. Miller, Igor Rakov
  • Wrinkling Prevention or Remedy with Adam Activity Inhibiting Substance
    Publication number: 20080319084
    Abstract: A composition contains a substance, which is capable of inhibiting activity of ADAM (a disintegrin and metalloprotease) present in a skin, in a proportion efficient for preventing or remedying wrinkling. Wrinkling is prevented or remedied with a method comprising the step of applying a substance, which is capable of inhibiting activity of ADAM present in a skin, to the skin. Anti-wrinkling effects are evaluated with a method wherein enzymatic activity or a gene expression level of ADAM in a skin, a skin tissue, or cells is used as an index.
    Type: Application
    Filed: October 13, 2005
    Publication date: December 25, 2008
    Applicant: Shiseido Company, Ltd.
    Inventors: Yukiko Matsunaga, Satoshi Amano, Yuki Ogura
  • Inhibitors against activation of NF-kappaB
    Publication number: 20080311074
    Abstract: A method of inhibiting NF-?B activation in a mammal including a human, which comprises the step of administering an effective dose of a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:
    Type: Application
    Filed: April 11, 2008
    Publication date: December 18, 2008
    Applicant: INSTITUTE OF MEDICAL MOLECULAR DESIGN INC.
    Inventors: Susumu MUTO, Akiko ITAI
  • Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
    Publication number: 20080312237
    Abstract: Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.
    Type: Application
    Filed: July 18, 2008
    Publication date: December 18, 2008
    Inventors: Michael G. Kelly, Satyanarayana Janagani, Ravindra B. Upasani
  • Anti-Radical Agents
    Publication number: 20080305055
    Abstract: Compounds of the formulae (1), (2) and selected hindered nitroxyl, hydroxylamine and hydroxylamine salt compounds such as the compound of formula (3), wherein Gi is hydrogen; C1-C22alkyl; C1-C22alkylthio; C2-C22alkylthioalkyl; C5-C7cycloalkyl; phenyl; C7-C9phenylalkyl; or SO3M; G2 is C1-C22alkyl; C5-C7cycloalkyl; phenyl; or C7-C9phenylalkyl; E is oxyl or hydroxyl; V is —O—; or —NH—; a is 0 or 1 or 2; b, c and d and g are each independently of one another 0 or 1; e is an integer from 1 to 4; f, m, n and p are each independently of one another an integer from 1 to 3; q is 0 or an integer from 1 to 3; Q, T and G3 are as defined in claim 1; G4 and G5 are each independently of the other hydrogen; or C1-C22alkyl; exhibit marked antiinflammatory action.
    Type: Application
    Filed: October 24, 2005
    Publication date: December 11, 2008
    Inventors: Werner Baschong, Oliver Reich, Sebastien Mongiat
  • Stabilized Compositions Comprising a Therapeutically Active Agent, and an Oxidizing Preservative
    Publication number: 20080300315
    Abstract: Citric acid and conjugate bases thereof are useful for stabilizing stabilized chlorine dioxide in the presence of therapeutically active agents and excipients in a composition. Ophthalmic compositions and methods related thereto are also disclosed herein.
    Type: Application
    Filed: May 19, 2005
    Publication date: December 4, 2008
    Inventors: Robert T. Lyons, Robert S. Jordan
  • Cooling Compounds
    Publication number: 20080300314
    Abstract: Compounds of the formula I give a cooling sensation to the mouth and skin: In Formula I, m is 0 or 1; X is —(CH2)n—R, where n is 0 or 1 and R is selected from —OR?. —COOH, —COOR?, —SO2NH2, —CHO, —COR??, and —CN, R? being selected from H and C1-C3 straight- and branched-chain alkyl. R? from C1-C4 straight- and branched-chain alkyl and R?? from C1-C3 straight- and branched-chain alkyl: Y is selected from H, —COOH and —OR??, where R?? has the significance previously referred to; and Z is H; with the provisos that (iii) When Y is H and X is any of the abovementioned significances, except —CN and —COOH, X is in the 4-position; (iv) when Y has a significance other than H, it is in the 5-position when X is in the 2-position and in the 6-position when X is in the 3-position. The compounds give a cooling sensation that can be more powerful than the best current commercial materials.
    Type: Application
    Filed: June 30, 2008
    Publication date: December 4, 2008
    Applicant: Givaudan SA
    Inventors: Christophe C. Galopin, Pablo Victor Krawec, Jay Patrick Slack, Lori W. Tigani, Stefan Michael Furrer
  • Compositions and Methods For Inhibiting an Isoform of Human Manganese Superoxide Dismutase
    Publication number: 20080287548
    Abstract: The present invention is directed to methods of modulating the activity of an isoform of manganese superoxide dismutase which is useful for the treatment of diseases such as neurodegenerative diseases and heart failure.
    Type: Application
    Filed: February 8, 2006
    Publication date: November 20, 2008
    Inventor: Paul Q. Anziano
  • ARYLMETHYLEN SUBSTITUTED N-ACYL-Y-AMINOALCOHOLS
    Publication number: 20080287493
    Abstract: The present invention relates to arylmethylen substituted N-acyl-Y-aminoalcohols of the general formula I in which Q, X, W, R1, R2, R3, R4 and R5 have the meaning as defined in the description. The compounds according to the invention are effective FSH modulators and can be used for example for fertility regulation in men or in women.
    Type: Application
    Filed: April 24, 2008
    Publication date: November 20, 2008
    Inventors: Lars Wortmann, Bernd Menzenbach, Marcus Koppitz, Dirk Kosemund, Hans-Peter Muhn, Anna Schrey, Ronald Kuhne, Thomas Frenzel, Florian Peter Liesener
  • Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists
    Publication number: 20080242657
    Abstract: Histamine H3 inverse agonists or histamine H3 antagonists are useful, alone or in combination with a neuroleptic agent, for treating or preventing movement disorders, including tremor, such as essential tremor, and tremor associated with Parkinson's disease, cranofacial trauma, multiple sclerosis, stroke, dystonia, and neuropathic, toxic or drug induced tremor.
    Type: Application
    Filed: March 22, 2005
    Publication date: October 2, 2008
    Inventors: Michael J. Marino, Guy R. Seabrook
  • Method For Inhibiting Tnf-Alpha
    Publication number: 20080234385
    Abstract: The present invention encompasses methods for inhibiting TNF-alpha expression with N-substituted dopamine derivatives. In this method a cell is administered a pharmaceutically effective amount of N-acetyl dopamine derivatives or N-alkyldopamine derivatives and a pharmaceutically acceptable carrier for treating a cell, preferably in an animal or human suffering from overexpression or abundant TNF-alpha. The N-acetyldopamine derivative or N-alkyldopamine derivatives may be administered alone or in combination with N-acetylserotonin (NAS) or other compound to inhibit TNF-alpha expression. Also disclosed is a method of treating a TNF-alpha related disease and/or disorder using such a compound.
    Type: Application
    Filed: July 26, 2006
    Publication date: September 25, 2008
    Applicant: CARITAS ST. ELIZABETH'S MEDICAL CENTER
    Inventors: Gregory Oxenkrug, Bertrand L. Jaber, Mary C. Perianayagam
  • Chemical Compounds
    Publication number: 20080234199
    Abstract: Triphenylethylene compounds of formula (I) are provided. The compounds are particularly useful for selective estrogen receptor modulation.
    Type: Application
    Filed: November 22, 2006
    Publication date: September 25, 2008
    Inventor: Subba Reddy Katamreddy
  • Protection against and treatment of hearing loss
    Patent number: 7427608
    Abstract: The present invention provides a method for protecting against or treating hearing loss in a subject. This method involves administering an effective amount of a protein tyrosine kinase inhibitor to the subject to protect against or to treat hearing loss.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: September 23, 2008
    Assignees: The Research Foundation of State University of New York, Health Research, Inc.
    Inventors: Thomas Nicotera, Donald Henderson, David G. Hangauer, Jr.
  • Hydroxybenzoic Acid Amides and the Use Thereof For Masking Bitter Taste
    Publication number: 20080214675
    Abstract: The use is described of hydroxybenzoic acid amides having formula (I) wherein R1 to R5 mutually independently denote hydrogen, hydroxy, methoxy or ethoxy, with the proviso that at least one of the radicals R1 to R5 denotes hydroxy. and R6 denotes hydrogen, methyl or ethyl and n denotes 1 or 2, their salts and mixtures thereof, to mask or reduce the unpleasant flavour impression of an unpleasantly tasting substance and/or to strengthen the sweet flavour impression of a sweet substance.
    Type: Application
    Filed: August 2, 2005
    Publication date: September 4, 2008
    Applicant: SYMRISE GMBH & CO. KG
    Inventors: Jakob Ley, Heinz-Jurgen Bertram, Gunter Kindel, Gerhard Krammer
  • Vitamin D Receptor Modulators
    Publication number: 20080200552
    Abstract: The present invention relates to novel, non-secosteroidal, hydroxyl substituted, carbon-linked diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
    Type: Application
    Filed: November 16, 2004
    Publication date: August 21, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: Emilio Enrique Bunel, Robert Peter Gajewski, Charles David Jones, Jianliang Lu, Sunil Nagpal, Tianwei Ma, Ying Kwong Yee
  • Administration of 2-oxyacetamide compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting the depigmentation and/or bleaching thereof
    Publication number: 20080166310
    Abstract: A regime or regimen for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for preventing and/or limiting the depigmentation and/or bleaching and/or for preventing and/or limiting the canities thereof, more particularly of human keratin fibers such as the hair, beard hair, moustache hair, the eyelashes and the eyebrows, includes administering to an individual in need of such treatment at least one 2-oxyacetamide compound of formula (I), or a salt and/or solvate thereof:
    Type: Application
    Filed: December 10, 2007
    Publication date: July 10, 2008
    Applicant: L'OREAL
    Inventors: Roger Rozot, Philippe Breton, Michel Neuwels, Christophe Boulle
  • Ctgf Expression Inhibitor
    Publication number: 20080167347
    Abstract: A CTGF expression inhibitor comprising a compound of the formula I: a pharmaceutically acceptable salt or solvate thereof as an active ingredient, (wherein Y is hydroxy or a group of the formula: —NH—SO2—Y? (wherein Y? is optionally substituted aryl or optionally substituted alkyl), and R1 to R9 are each independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkoxy or the like).
    Type: Application
    Filed: January 19, 2006
    Publication date: July 10, 2008
    Applicant: SHIONGI & CO., LTD.
    Inventors: Kaoru Seno, Toshihiro Shinosaki, Satoshi Hata, Isamu Yamada, Hiroki Sato, Mikayo Hayashi
  • Small molecules used to increase cell death
    Patent number: 7390836
    Abstract: The invention features methods for increasing cell death. The invention also features compounds used to increase cell death. The invention further features methods for identifying compounds that increase cell death.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: June 24, 2008
    Assignee: President and Fellows of Harvard College
    Inventors: Junying Yuan, Alexei Degterev, Timothy J. Mitchison
  • Low temperature processes for making cyclic lipid implants for intraocular use
    Publication number: 20080145403
    Abstract: Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.
    Type: Application
    Filed: December 19, 2006
    Publication date: June 19, 2008
    Applicant: ALLERGAN, INC.
    Inventors: Lon T. Spada, James N. Chang, Michelle Luu
  • Non-nucleoside reverse transcriptase inhibitors
    Patent number: 7388111
    Abstract: The present invention provides for compounds useful for treating an HIV-1 infection, or preventing an HIV-1 infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1-R4 and Ar are as herein defined.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: June 17, 2008
    Assignee: Roche Palo Alto LLC
    Inventors: Taraneh Mirzadegan, Tania Silva
  • Glucagon Receptor Antagonists, Preparation and Therapeutic Uses
    Publication number: 20080125468
    Abstract: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
    Type: Application
    Filed: May 13, 2005
    Publication date: May 29, 2008
    Inventors: Mark Donald Chappell, Scott Eugene Conner, Isabel Cristina Gonzalez Valcarcel, Jason Eric Lamar, Jianke Li, Julie Sue Moyers, Rebecca Anne Owens, Allie Edward Tripp, Guoxin Zhu
  • C-Kit Modulators And Methods Of Use
    Publication number: 20080096892
    Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellu-lar activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Even more specifically, the invention provides compounds for modulating c-Kit kinase activity and methods of treating diseases mediated by c-Kit activity utilizing the compounds and pharmaceutical compositions thereof.
    Type: Application
    Filed: August 27, 2004
    Publication date: April 24, 2008
    Applicant: Exelixis, Inc.
    Inventors: Wei Cheng, Erick Wang Co, Moon Hwan Kim, Rhett Ronald Klein, Donna T. Le, Amy Lew Tsuhako, John M. Nuss, Wei Xu, William Bajjalieh
  • Pest control agent composition and method of using the same
    Patent number: 7361653
    Abstract: The present invention relates to a composition for noxious organisms-controlling agent having a synergistic effect and a method for using said composition, which comprises, as active ingredients thereof, one or more compounds selected from the phthalamide derivatives represented by general formula (I) being useful as an insecticide or acaricide and one or more compounds selected from the compounds having insecticidal, acaricidal or nematocidal activity: wherein R1, R2 and R3 may be the same or different and each represent hydrogen atom, C3-C6 cycloalkyl, -A1-Qp, etc., each of X and Y may be the same or different and represents hydrogen atom, halogen atom, etc., n is an integer of 1 to 4, m is an integer of 1 to 5, and each of Z1 and Z2 represents O or S.
    Type: Grant
    Filed: April 16, 2002
    Date of Patent: April 22, 2008
    Assignee: Nihon Nohyaku Co., Ltd
    Inventors: Kazuyuki Sakata, Masayuki Morimoto, Hiroshi Kodama, Tetsuyosi Nishimatsu
  • Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
    Patent number: 7351719
    Abstract: The present invention relates to amide compounds of general formula I wherein the groups and residues A, B, b, W, X, Y, Z, R1, R2 and R3 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one amide according to the invention. In view of the MCH receptor-antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: April 1, 2008
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Dirk Stenkamp, Stephan Georg Mueller, Gerald Juergen Roth, Philipp Lustenberger, Klaus Rudolf, Thorsten Lehmann-Lintz, Kirsten Arndt, Ralf Lotz, Martin Lenter, Heike-Andrea Wieland
  • Non-nucleoside reverse transcriptase inhibitors
    Publication number: 20080020981
    Abstract: The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, X1 and X2 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.
    Type: Application
    Filed: July 20, 2007
    Publication date: January 24, 2008
    Inventor: Zachary Kevin Sweeney
  • Active substance combinations having insecticidal and acaricidal properties
    Patent number: 7288572
    Abstract: The present invention relates to novel insecticidally and acaricidally active compound combinations of N2-[1,1-dimethyl-2-(methylsulphonyl)ethyl]-3-iodo-N1-{2-methyl-4-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl}phthalamide of the formula (I) and active compounds identified in the disclosure.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: October 30, 2007
    Assignee: Bayer CropScience AG
    Inventors: Jörg Konze, Wolfram Andersch, Dietrich Stübler, Rüdiger Fischer
  • Pyrazolecarboxamide and pyrazolethioamide as fungicide
    Patent number: 7173055
    Abstract: Novel pyraole derivatives of formula (I), wherein: X is oxygen or sufu, R1 is C1–C3alkyl, C1–C3haloalkyl, C1–C3alkoxy-C1–C3alkyl or C1–C3haloalkoxy-C1–C3alkyl; R2 is C1–C3haloalkyl; and R3 is halogen. The novel compounds have plant-protective properties and are suitable for protecting plants against infestations by phytopathogenic microorganisms.
    Type: Grant
    Filed: November 11, 2000
    Date of Patent: February 6, 2007
    Assignee: Syngenta Crop Protection, Inc.
    Inventor: Harald Walter
  • Devices and methods for eliminating termite colonies
    Patent number: 7157078
    Abstract: This invention relates to devices, kits, and methods for eliminating termite colonies. The kits, devices, and methods employ a termiticidal bait matrix containing a) a termiticide selected such that the termiticide causes death to about 50 to about 100% of termites within about 24 to about 84 days after the termites begin to ingest the termiticide or the bait matrix comprising the termiticide, b) a cellulose containing material, and c) water. The termiticidal bait matrix can be used in a bait station installed in the ground. The kits are suitable to be used by consumers in their homes.
    Type: Grant
    Filed: February 2, 2004
    Date of Patent: January 2, 2007
    Assignee: The University of Florida Research Foundation, Inc.
    Inventors: Philip Frederick Brode, III, Garry Steven Garren, Leo Timothy Laughlin, Randall Stryker Matthews, Dale Edwin Barker, Daniel James Kinne, Gary Eugene McKibben, Christopher Miles Miller, Timothy Robert Probst
  • UV-absorbing lipid vesicles
    Patent number: 7147866
    Abstract: Highly effective vesicular compositions from UV-absorbing lipids are described in the present invention. Combination of UV-absorbing property and the vesicular delivery system results in higher levels of photoprotection to skin and hair. The vesicular compositions of the present invention are made from cationic UV-absorbing lipids of Formula I wherein, ArCO is selected from cinnamoyl, p-methoxy cinnamoyl, p-N,N-dimethylamino benzoyl and combinations thereof, R1 is selected from saturated or unsaturated alkyl group with carbons ranging from C10 to C22.
    Type: Grant
    Filed: September 29, 2004
    Date of Patent: December 12, 2006
    Assignee: Galaxy Surfactants Limited
    Inventors: Nirmal Madhukar Koshti, Shubhangi Dattaram Naik, Tanaji Shamrao Jadhav
  • Vehicle for topical delivery of anti-inflammatory compounds
    Patent number: 7138394
    Abstract: A vehicle for topical delivery which contains a liquid eutectic mixture of hydrophobic compounds.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: November 21, 2006
    Assignee: Alpharx Inc.
    Inventors: Joseph Schwarz, Michael Weisspapir
  • Compounds and compositions for delivering active agents
    Patent number: 7138546
    Abstract: Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.
    Type: Grant
    Filed: August 16, 2001
    Date of Patent: November 21, 2006
    Assignee: Emisphere Technologies, Inc.
    Inventor: Pingwah Tang
  • Benzimidazole vascular damaging agents
    Patent number: 7081469
    Abstract: Vascular damaging agents composed of substituted 5(6)-substituted benzimidazole-2-carbamates are provided. These agents are useful in the preparation of medicaments for the treatment of diseases involving neovascularisation, particularly for the treatment of solid tumors, macular degeneration, diabetic retinopathy, rheumatoid arthritis, psoriasis, and atherosclerosis. Embodiments include a 5(6)-substituted benzimidazole-2-carbamate of formula I wherein A represents a multi-substituted alkyl group or aromatic ring.
    Type: Grant
    Filed: July 3, 2003
    Date of Patent: July 25, 2006
    Assignee: Angiogene Pharmaceuticals Ltd.
    Inventor: Peter David Davis
  • 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them
    Patent number: 7078407
    Abstract: The present invention relates to 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them. More particularly, it relates to 4-hydroxycinnamamide derivatives showing superior antioxidant activity compared to the known antioxidant compounds, their pharmaceutically acceptable salt, and pharmaceutical compositions containing them. It can be usefully used in treating neurodegerative diseases such as aging, cancer, diabetes, ischemic stroke, Parkin's disease, dementia and Huntinton's disease.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: July 18, 2006
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: No-Sang Park, Young-Sik Jung, Churl-Min Seong, Hee-Jong Lim, Joong-Ho Yoon, Jae-Yang Kong, Woo-Kyu Park
  • Compositions and methods for treating heart failure
    Patent number: 7053094
    Abstract: Certain substituted benzamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: January 20, 2005
    Date of Patent: May 30, 2006
    Assignee: Cytokinetics, Inc.
    Inventors: Fady Malik, Adam Lewis Tomasi, Bainian Feng, Erica Anne Kraynack, Kathleen A. Elias, Pu-Ping Lu, Whitney Walter Smith, Xiangping Qian, David J. Morgans, Jr.
  • Pharmaceutically active compounds and methods of use
    Patent number: 7041702
    Abstract: The present invention relates to pharmaceutically acceptable compounds, including acylguanidine compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for the treatment or prophylaxis of neurological injury and neurodegenerative disorders.
    Type: Grant
    Filed: October 20, 1998
    Date of Patent: May 9, 2006
    Assignee: Scion Pharmaceuticals, Inc.
    Inventors: Graham J. Durant, Seetharamaiyer Padmanabhan
  • Fluorobenzamides and uses thereof
    Patent number: 6951884
    Abstract: The invention relates to fluorobenzamide derivatives of the formula wherein R1, R2, R3 R4, R5, R6 and R7 are as defined herein. =, The compounds of the invention are selective monoamine oxidase B inhibitors and therefore they are suitable for the treatment of diseases mediated by monoamine oxidase B, such as Alzheimer's disease or senile dementia.
    Type: Grant
    Filed: June 6, 2003
    Date of Patent: October 4, 2005
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Synese Jolidon, Rosa Maria Rodriguez Sarmiento, Andrew William Thomas, Rene Wyler
  • NF-?B inhibitor comprising phenylmethyl benzoquinone as the active ingredient
    Patent number: 6943196
    Abstract: An NF-?B inhibitor having as an active ingredient a benzoquinone derivative represented by the general formula (1) wherein R1, R2, and R3 are each independently H, alkyl having 1 to 5 carbons, or alkoxy having 1 to 5 carbons; R4 is H, hydroxymethyl, alkyl, or carboxyl which is optionally esterified or amidated; Z is represented by the formula (A); and, n is an integer from 0 to 6, or its hydroquinone form or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 19, 1999
    Date of Patent: September 13, 2005
    Assignee: Daiichi Suntory Pharma Co., Ltd.
    Inventors: Yoichi Nunokawa, Kenji Suzuki, Masayuki Saitoh
  • Compositions and methods for treating heart failure
    Patent number: 6908923
    Abstract: Certain substituted benzamide derivatives of Formula I: selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: June 21, 2005
    Assignee: Cytokinetics, Inc.
    Inventors: Fady Malik, Adam Lewis Tomasi, Bainian Feng, Erica Anne Kraynack, Kathleen A. Elias, Pu-Ping Lu, Whitney Walter Smith, Xiangping Qian, David J. Morgans, Jr.
  • Anti-viral compositions and methods of making and using the anti-viral compositions
    Patent number: 6855341
    Abstract: Disclosed are anti-viral compositions containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients), and a pharmaceutical carrier. Also disclosed are methods of treating lesionous symptoms of a viral infection involving applying an effective amount of the anti-viral composition to the lesions.
    Type: Grant
    Filed: November 4, 2002
    Date of Patent: February 15, 2005
    Inventor: Jeffrey B. Smith
  • Modulators of cysteine protease
    Patent number: 6828350
    Abstract: The present invention concerns novel mediators of the activity of picornavirus 3C protease and the modulation of the activity of other similar proteins. The modulators may be used in pharmaceutical compositions either for inhibition of 3C protease (for example in viral infections) or for the enhancement of the activity of proteins similar to the 3C protease such as Apopain (for induction of apoptosis).
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: December 7, 2004
    Assignee: Exegenics Inc.
    Inventors: Dorit Arad, Yuval Elias
  • N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives
    Publication number: 20040242685
    Abstract: The present invention relates to N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives having the general formula I 1
    Type: Application
    Filed: July 19, 2004
    Publication date: December 2, 2004
    Inventors: John Richard Morphy, Zoran Rankovoc
  • New 3-aryl propionic acid derivatives and analogs
    Publication number: 20040229949
    Abstract: Novel 3-aryl propionic acid derivatives and analogs, process and intermediate for their manufacture, pharmaceutical preparations containing them and the use of the compounds in clinical conditions associated with insulin resistance.
    Type: Application
    Filed: October 2, 2003
    Publication date: November 18, 2004
    Inventors: Kjell Andersson, Maria Boije, Johan Gottfries, Tord Inghardt, Lanna Li, Eva-Lotte Lindstedt Alstermark
  • Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
    Patent number: 6803386
    Abstract: The present invention is directed to a pharmaceutical composition containing a cancer-treating effective amount of a class of prostacyclin derivatives, and a pharmaceutically acceptable carrier, and to kits and methods of employing the same for the treatment of cancer.
    Type: Grant
    Filed: January 16, 2002
    Date of Patent: October 12, 2004
    Assignee: United Therapeutics Corporation
    Inventors: Robert Shorr, Martine Rothblatt
  • Diphenyl derivatives
    Patent number: 6777442
    Abstract: The present invention relates to compounds of the general formula (I) in which X represents O, S, SO, SO2, CH2, CHF, CF2 or NR8, and Z represents a group of the formula in which A represents O or S, the subscript “a” is 0 or 1, group D represents a straight-chain (C1-C4)-alkylene group, and R36 represents OR37 or NR38R39. It also relates to processes for preparation of such compounds and to their use in medicaments for the treatment of depression, goiter, cancer of the thyroid gland, arteriosclerosis, hypercholesterolaemia, dyslipidaemia, obesity, cardiac insufficiency, pulmonary emphysema, pain, migraine, Alzheimer's disease, osteoporosis, cardiac arrhythmias, hypothyroidism, skin disorders or diabetes.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: August 17, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Helmut Haning, Michael Woltering, Gunter Schmidt, Christiane Faeste, Hilmar Bischoff, Axel Kretschmer, Verena Vöhringer, Peter Ellinghaus
  • Veterinary compositions for the treatment of parasitic diseases
    Patent number: 6777448
    Abstract: Micellar non-aqueous or aqueous compositions for the therapeutic treatment of animal diseases caused by parasitic worms or nematodes, comprising rafoxanide and specific combinations of solvents which act as stabilising and absorption promoting agents. The solvents are selected from non-ionic surface-active agents such as Tween®-80 and from N-methylpyrrolidone, 2-pyrrolidone or dimethylsulfoxide. The compositions are easy to prepare, stable upon storage and can be administered orally, by injection or topically. With these formulations, an improvement of the efficacy of rafoxanide in the treatment of the diseases is observed.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: August 17, 2004
    Assignee: New Pharma Research Sweden AB
    Inventor: Abdul Rahman Shoa'a
  • Novel crystal of n-hydroxy-2 (s)-methyl-5-ethoxymethoxy-4(s)-[n-(4-phenoxyphenylcarbonyl)amino] pentanamide, process for their production and medicines containing the crystals as the active ingredient
    Publication number: 20040152785
    Abstract: The present invention relates to a novel crystal of a compound of formula (I).
    Type: Application
    Filed: July 22, 2003
    Publication date: August 5, 2004
    Inventors: Shigehiro Okuyama, Masaki Okamoto
  • Farnesyl derivatives and pharmaceutical compositions containing them
    Patent number: RE39682
    Abstract: Novel farnesyl derivatives which are inhibitors of the prenylated protein methyltransferase enzyme, and useful as anti-cancer drugs, have the following formula: wherein R1represents farnesyl, geranyl or geranyl-geranyl; Z represents C—R6 or N; R2 represents H, CN, the groups COOR7, SO3R7, CONR7R8 and SO2NR7R7, wherein R7 and R8 are each independently hydrogen, alkyl, alkenyl, and the groups COOM and SO3M, wherein M is a cation; R3, R4, R5 and R6 are each independently hydrogen, carboxyl, alkyl, alkenyl, aminoalkyl, nitroalkyl, nitro, halo, amino, mono- or di-alkylamino, mercapto, mercaptoalkyl, azido, or thiocyanato; X represents O, S, SO, SO2, NH or Se; and the quaternary ammonium salts and N-oxides of the compounds of formula I wherein Z is N.
    Type: Grant
    Filed: March 30, 2005
    Date of Patent: June 5, 2007
    Assignee: Ramot at Tel Aviv University Ltd.
    Inventor: Yoel Kloog